European equities traded in the US as American depositary receipts were moving higher late Friday morning, rising 0.55% to 1,424.23 on the S&P Europe Select ADR Index, which is poised to end the week about 0.31% higher.
From continental Europe, the gainers were led by biopharmaceutical company Genfit (GNFT) and semiconductor company Sequans Communications (SQNS), which advanced 10% and 2.5% respectively. They were followed by biopharmaceutical company Cellectis (CLLS) and pharmaceutical company Novo Nordisk (NVO), which increased 2% and 1.8% respectively.
The decliners from continental Europe were led by medical device maker EDAP TMS (EDAP) and biopharmaceutical company Grifols (GRFS), which fell 2.5% and 1.6% respectively. They were followed by biotech firm Evaxion Biotech (EVAX) and telecommunications company Nokia (NOK), which were down 1.1% and 0.6% respectively.
From the UK and Ireland, the gainers were led by biotech firm Trinity Biotech (TRIB) and biopharmaceutical company Bicycle Therapeutics (BCYC), which climbed 9.9% and 3.5% respectively. They were followed by software firm Endava (DAVA) and biotech firm Autolus Therapeutics (AUTL), which rose 2.8% and 1.6% respectively.
The decliners from the UK and Ireland were led by biopharmaceutical company Akari Therapeutics (AKTX) and insurance company Prudential (PUK), which lost 8.4% and 1.3% respectively. They were followed by telecommunications operator Vodafone Group (VOD) and pharmaceutical company GSK (GSK), which were off 0.9% each.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。